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tomography (CT) revealing ascites and omental caking. She underwent
paracentesis with removal of 1000 mL of ascites but needed an addi-
tional paracentesis two weeks later removing an additional 4100 mL.
She was referred to a gynecologic oncologist.
Physical examination
The patient's condition was fair and she appeared to be in no
distress. Other than tachycardia, vital signs were normal. AbdominalIntroduction
Malignant peritoneal mesothelioma (MPM) is a rare, aggressive
tumor. 15% of mesotheliomas arise from the peritoneum as opposed
to the pleura. MPM's prevalence in the United States is 1–2/1,000,000.
With an estimated 400 new cases, MPM accounts for 0.024% of all
new cancers diagnosed annually (Howlader et al., 1975–2011; Bridda
et al., 2007).MPM is rapidly fatalwith amedian survival of 6–12months
and mean symptom-to-survival time of 345 days. Untreated, survival is
approximately six months. The principal risk factor for acquiring the
disease, history of asbestos exposure is evident in only 50% of patients
with peritoneal mesothelioma (Bridda et al., 2007).Case report
We present a 67 year old postmenopausal female with worsening
abdominal bloating, distension and early satiety for one month.
The patient's history included stage I (pT1N0) inﬁltrating ductal car-
cinoma of the left breast treated with lumpectomy in 1997 followed by
adjuvant chemoradiation, iron deﬁciency anemia, depression, and hiatal
hernia. She is a nonsmoking, retired teacher of Ashkenazi Jewish decent
with negative BRCA testing, and no known asbestos exposure. Family
history was signiﬁcant for breast cancer in a paternal aunt.te, Department of Gynecologic
. Fax: +1 716 845 7608.
.org (K.S. Grzankowski).
. This is an open access article underexam revealed distension and tenderness on palpation, but no mass.
Pelvic exam revealed normal female genitalia with no masses noted
on bimanual rectovaginal exam.
Laboratory data
Her CA-125 was 188 U/mL; CA 27–29 was 91 U/mL; and CEA was
1.1 ng/mL.
Histological ﬁndings
Histocytological assessment of collected asciteswas read as “atypical
epithelioid cellsmixedwithmesothelial cells, cannot exclude adenocar-
cinoma or mesothelioma”, although no purely malignant cells were
identiﬁed. Singly dispersed cells with vacuolated cytoplasm with
targetoid appearance suspicious for breast carcinoma were identiﬁed.
Immunohistochemical (IHC) reactivity was not seen for ER or MOC-
31, markers for breast cancer distinguishing between mesothelioma
and adenocarcinoma. These cells were positive for calretinin found in
both benign mesothelial cells and mesothelioma (Fig. 1A–B).
Treatment and follow-up
The ﬁndings of ascites, omental caking, and elevated CA-125 in
conjunction with her symptomatology that included pain, weight loss,
bloating, nausea, poor appetite, and weakness, suggested primary
peritoneal cancer versus recurrentmetastatic breast cancer thus the pa-
tient underwent exploratory laparotomy. Omental tumor frozen section
assessment was reported as serous adenocarcinoma, consistent with
primary peritoneal origin. At this point the decision was made to
performdebulking surgerywith total abdominal hysterectomy, bilateral
salpingo-oophorectomy, infracolic omentectomy, and resection ofthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. A) Mid-power view showing the mainly papillary architecture of this primary peritoneal mesothelioma. Note the proliferation of malignant epithelioid type mesothelial cells.
Hematoxylin–eosin (H&E) stain. Originalmagniﬁcation 100×. B)Higherpower viewof the tumor showing the classicmalignantmesothelial cell features. H&E stain. Originalmagniﬁcation
400×. Supporting thediagnosis ofmalignantmesothelioma: C) strong calretinin positivity. Originalmagniﬁcation 100×.D) StrongD2-40positivity. Originalmagniﬁcation 100×. E) Strong
CK5/6 positivity. Original magniﬁcation 200×.
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were 1 cmnodules and plaques in the small and large bowelmesentery,
posterior surface of the stomach, and gastro-hepatic ligament towards
the porta hepatis that were left.
Final pathology revealed MPM in the omentum and uterus. There
was surface involvement of bilateral ovaries and tumor involving the
para-tubal soft tissues. IHC was positive for WT-1, calretinin, D2-40,
and cytokeratin (CK) 5/6, and negative for CK7, ER, mammaglobin,
PAX-8, and CK20. Although IHC can assist in identifying mesothelial
cells, none are speciﬁc for mesothelioma. CK5/6, calretinin and WT-1
are used collectively for mesothelioma (Fig. 1C–E).
The patient was referred to thoracic medical oncology who initiated
chemotherapy with cisplatin 60 mg/m2 and pemetrexed 500 mg/m2
every 21 days for 4 cycles. CT after completion of treatment showed
mesenteric stranding, but overall improvement of disease. She has
been continued on maintenance pemetrexed every 3 weeks. The most
recent abdominopelvic CT scan a year from diagnosis revealed no
interval change with stable mesenteric stranding and nodularity.
Discussion
The histological diagnosis of MPM can often be challenging. For this
patient ascites was examined for MOC-31 and ER to try to differentiate
mesothelioma and adenocarcinoma. MOC-31 has good sensitivity and
speciﬁcity for generic adenocarcinoma of 92% and 87%, respectively.
MOC-31 is seen in approximately 7% of malignant mesotheliomas.
ER is positive in most breast cancers; ~70% in the well-moderately dif-
ferentiated types, and ~20% in poorly differentiated types. ER positivity
is low in mesotheliomas at around 10%. ER is included in IHC panels to
distinguish peritoneal serous carcinoma from malignant peritoneal me-
sothelioma, where ER positivity favors serous cancer (Ordóñez, 2005,
2006). Although frozen section can accurately diagnose malignancy inthe majority of cases, they are often called serous in the setting of
MPM. This is especially true in the low grade papillary subtypes of me-
sothelioma as this pathology often tops the differential in women of
post-reproductive agewith the clinical ﬁndings of ascites, peritoneal in-
volvement, and omental caking. They can be distinguished readily on
permanent section and with the addition of the IHC as described in
the ﬁgure caption. This tumor on permeant ﬁxation showed predomi-
nantly a surface/encasing type growth with papillae. On higher power
the cells in this tumor were globally blander as compared to a typical
serous carcinoma and had features of classic mesothelial cells. The IHC
panel with positive CK5/6, calretinin, and D2-40 supported the diagno-
sis of MPM.
There is no consensus on the optimal treatment for MPM, and most
available clinical data is derived from retrospective studies and case re-
ports. Treatment entails a combination of palliative cytoreductive
surgery, chemotherapy, and rarely, radiation (Vogelzang et al., 2003).
Over the last decade cytoreductive surgery and hyperthermic intraper-
itoneal chemotherapy (HIPEC) among centers with expertise in this
form of therapy, resulted in median survival approaching ﬁve years for
appropriately selected patients and is considered a ﬁrst line recommen-
dation (Haslinger et al., 2013). A multi-institutional registry study
evaluated cytoreductive surgery combined with HIPEC for diffuse,
malignant, peritoneal mesothelioma. Among 401 patients enrolled,
187 (46%) had complete or near-complete cytoreduction, and 372
(92%) receivedHIPEC. Of theHIPEC patients, 311 (83%) received cisplat-
in and doxorubicin. The median follow-up period was 33 months. The
overall median survival was 53 months (1–235 months), and 3- and
5-year survival rates were 60% and 47%, respectively. Four prognostic
factors were independently and signiﬁcantly associated with improved
survival in a multivariate analysis: epithelial subtype, absence of lymph
node metastasis, completeness of cytoreduction, and use of HIPEC
(Yan et al., 2009).
12 K.S. Grzankowski et al. / Gynecologic Oncology Reports 11 (2015) 10–12The patient in this case report had residual tumor up to 1 cm,making
HIPEC a poor choice for treatment, as the upper limit for this modality is
2.5 mm. Therefore systemic chemotherapy was indicated. Most clinical
trials for chemotherapy in mesothelioma have excludedMPM, and data
has been extrapolated from patients with pleural mesothelioma. The
addition of pemetrexed to cisplatin, the singlemost active agent against
malignant mesothelioma, was associated with signiﬁcantly improved
survival with greater antitumor activity compared with cisplatin
alone. Median survival in the pemetrexed/cisplatin armwas 12.1 versus
9.3 months in the control arm. Median time to progression was signiﬁ-
cantly longer in the pemetrexed/cisplatin arm: 5.7 versus 3.9 months.
Response rates were 41.3% in the pemetrexed/cisplatin arm versus
16.7% in the control arm (Vogelzang et al., 2003). One analysis on
MPM, speciﬁcally pemetrexed with or without cisplatin had a favorable
safety proﬁle, and a 25% response rate in chemotherapy-naïve patients
indicated activity in this patient population (Janne et al., 2005). Ongoing
trials are investigating the efﬁcacy of maintenance pemetrexed inMPM.
Prolonged progression free survival has been seen in pleural mesotheli-
oma with this treatment.Conﬂict of interest statement
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